The major novelty of this study is demonstrating that the expression of cyclin D2 (cD2) is uniformly decreased in all tested conditions related to the pathomechanism of Alzheimer’s disease (AD), including Aβ toxicity, neuroinflammation and human post-mortem brain tissue from AD patients. This evidence concerns the gene CD2 and early-onset autosomal dominant Alzheimer disease.